 |
Top 111 medical and healthcare startups in Cambridge
Oct 04, 2025 | By Jason Kwon | 28 |
1
Funding: $21M
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
Aerska is a biotechnology company that is creating RNA medications to treat, postpone, and prevent brain disorders.
2
Funding: $435M
Lila Sciences creates a scientific superintelligence platform and autonomous labs for life sciences, chemistry, and materials science.
Lila Sciences creates a scientific superintelligence platform and autonomous labs for life sciences, chemistry, and materials science.
3
Funding: £7M
Healthera is a provider of next-generation, pharmacy-integrated personal health management solutions.
Healthera is a provider of next-generation, pharmacy-integrated personal health management solutions.
5
Funding: $66.5M
VideaHealth is offers dentistAI’s software automatically detects pathologies in dental imaging, helping dentists avoid missing diseases.
VideaHealth is offers dentistAI’s software automatically detects pathologies in dental imaging, helping dentists avoid missing diseases.
6
Funding: $35.6M
We design and develop the world's smallest and most accurate wearable devices for medical research and epilepsy management.
We design and develop the world's smallest and most accurate wearable devices for medical research and epilepsy management.
7
Funding: £20.7M
Sano Genetics is a personalised medicine research platform with data privacy and transparency at its core.
Sano Genetics is a personalised medicine research platform with data privacy and transparency at its core.
8
Funding: £12.5M
Shift Bioscience is creating new drug targets and diagnostic tools to enhance healthy lifespan through the repair of mitochondrial genes that cause neurodegenerative diseases or coronary heart disease.
Shift Bioscience is creating new drug targets and diagnostic tools to enhance healthy lifespan through the repair of mitochondrial genes that cause neurodegenerative diseases or coronary heart disease.
9
Funding: $11.5M
PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.
10
Funding: £6.2M
Zetta Genomics manages large-scale genomic data for precision medicine.
Zetta Genomics manages large-scale genomic data for precision medicine.
11
Funding: £1.5M
Cell Guidance Systems is a biotechnology company developing research tools for stem cell technology.
Cell Guidance Systems is a biotechnology company developing research tools for stem cell technology.
12
Funding: $3.9B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
13
Funding: $1.5B
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
Intellia is a leading genome editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing diseased genes in the human body through a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 genome editing and develop a potential new drug class.
14
Funding: $1.4B
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
15
Funding: $1.3B
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
16
Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
17
Funding: $1.1B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
18
Funding: $951.1M
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.
19
Funding: $931.6M
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
20
Funding: $656.4M
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
